Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00372307 |
Recruitment Status :
Completed
First Posted : September 6, 2006
Last Update Posted : December 28, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vitiligo Vulgaris | Drug: Application of pimecrolimus | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 26 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris |
Study Start Date : | May 2004 |
Actual Study Completion Date : | November 2004 |

- Repigmentation percentage of the reference lesion after 6 months.
- Number of patients with repigmentation after 3 and 6 months.
- Repigmentation percentage of the reference lesion after 3 months.
- Adverse events (month 3 and 6).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Active or stable vitiligo vulgaris
- lesions at head or neck + maximum 10% lesions at the rest of the body
Exclusion Criteria:
- Topica during last 2 weeks
- Photo(chemo)therapy during last 4 weeks
- Segmentary vitiligo

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00372307
Belgium | |
University Hospital Ghent | |
Ghent, Belgium, 9000 |
Principal Investigator: | Jean-Marie Naeyaert, MD, PhD | University Hospital, Ghent |
Additional Information:
Publications:
ClinicalTrials.gov Identifier: | NCT00372307 History of Changes |
Other Study ID Numbers: |
2003/275 |
First Posted: | September 6, 2006 Key Record Dates |
Last Update Posted: | December 28, 2007 |
Last Verified: | December 2007 |
Additional relevant MeSH terms:
Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases Pimecrolimus Tacrolimus Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Dermatologic Agents Immunosuppressive Agents Immunologic Factors Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |